FINDINGS OF SCIENTIFIC MISCONDUCT NIH GUIDE, Volume 24, Number 18, May 19, 1995 P.T. 34 Keywords: Ethics/Values in Science & Technol Grants Administration/Policy+ Department of Health and Human Services Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following cases: Denise R. Conrad, University of Iowa: The Division of Research Investigations (DRI) of the Office of Research Integrity (ORI) reviewed an investigation conducted by the University of Iowa into possible scientific misconduct on the part of Ms. Denise R. Conrad, formerly a Research Assistant in the Department of Preventive Medicine, College of Medicine. ORI found that Ms. Conrad committed scientific misconduct by fabricating or falsifying data on questionnaires in biomedical research supported by Public Health Service grant R01 ES05653, \"Residential Radon and Lung Cancer Case- Control Study.\" Ms. Conrad has accepted the ORI findings and agreed to a Voluntary Exclusion Agreement under which Ms. Conrad is not eligible to apply for or receive any Federal grant or contract funds for a three-year period beginning April 10, 1995. The fabricated or falsified data did not appear in any publication. Catherine Coyle, ISOLAB, Inc.: An investigation conducted by the ISOLAB found that Ms. Coyle, a former laboratory technician, falsified and misreported the results of assays for fetal hemoglobin data generated for Johns Hopkins\' Multicenter Study of Hydroxyurea in Sickle Cell Anemia in biomedical research supported by Public Health Service funds under a cooperative agreement. Ms. Coyle admitted that she misrepresented data submitted to the Johns Hopkins clinical hydroxyurea study. There were no publications involved. Ms. Coyle executed a Voluntary Exclusion and Settlement Agreement in which she has agreed not to apply for Federal grant or contract funds and will not serve on PHS advisory committees, boards or peer review groups for a three-year period beginning March 27, 1995. Terence S. Herman, M.D., Harvard Medical School: The Division of Research Investigations (DRI) of the Office of Research Integrity (ORI) reviewed an investigation conducted by Harvard Medical School into possible scientific misconduct on the part of Dr. Herman while he was an employee of that institution. ORI concurred with the factual findings as set forth in the institution\'s report, and finds that Dr. Herman committed scientific misconduct by falsely reporting in a published article that research had been conducted according to a stated protocol when, in fact, Dr. Herman knew at the time that the protocol for tumor measurements had not been carried out exactly as described. The research was supported by grant awards from the National Cancer Institute and the National Center for Research Resources, National Institutes of Health. Dr. Herman accepted the misconduct finding as part of a Voluntary Settlement Agreement under which, for a period of three years, any institution which submits an application for PHS support for a clinical research project on which his participation is proposed or which uses him in any capacity on PHS supported clinical research must concurrently submit a plan for supervision of his duties. The supervisory plan must be designed to ensure the scientific integrity of Dr. Herman\'s research contribution. Dr. Herman also is prohibited from serving on any Public Health Service advisory committee, board, and/or peer review committee for a period of three years. He has agreed to submit a letter to the International Journal of Radiation Oncology, Biology, Physics requesting retraction of that portion of the article dealing with tumor response (Herman, et al., A Phase I-II Trial of Cisplatin, Hyperthermia and Radiation in patients with Locally Advanced Malignancies. Int. J. Radiation Oncology Biol. Phys. 17:1273-1278; 1989). INQUIRIES For further information, contact: Director Division of Research Investigations Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 Telephone: (301) 443-5330 .
